SENISCA secures additional £3.7 million financing to support rapid development of senotherapeutic platform to treat age-related disease
Summary
In addition to the total investor capital raised of \xa37.1 million to date, SENISCA, through prestigious Innovate UK grants, awards, and commercial relationships, has also gained an additional \xa31.1 million in non-dilutive funding and commercial revenue, further validating the potential of the Companys proprietary scientific approach.SENISCA, a spinout from the University of Exeter, has developed proprietary technology that harnesses RNA biology to reprogram aged senescent cells. Senescent cells, with a pro-inflammatory profile and disrupted function, are emerging as causal factors for multiple age-related diseases.SENISCA has identified a novel and druggable component of the cellular senescence response, RNA splicing dysregulation, which can be specifically targeted in the context of multiple pharmacological and skin health indications.The proceeds of SENISCAs largest fundraise to date will support continued rapid company evolution and the preclinical development of the Companys senotherapeutic programmes, that target the causes of age-related disease via RNA splicing regulation, resulting in cellular reprogramming and disease modification by attenuating senescence.Dr Sarah Cole, CEO of SENISCA, commented: This financing round represents another significant milestone for SENISCA. SENISCA has undergone a significant and rapid development and QantX is looking forward to working with the team to realise the full potential of the Companys disruptive senotherapeutic technology.SENISCA is an award-winning, RNA therapeutics spinout from the University of Exeter. In line with the rapid evolution of the company, R&D activities are focused on IND data generation.SENISCAs platform technology has broad applicability for multiple age-related diseases including those of the eyes, lungs, joints, and brain. Targeting these specific diseases will streamline progress towards the clinic by avoiding potential pitfalls of systemic delivery.SENISCAs novel senotherapeutics will be mined and commercialized through partnership or co-development models that will sit alongside internal programmes.